Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Globus Medical (GMED) stock in plain English

Free brief · no signupStart here
GMEDPublished Nov 15, 2026
Globus Medical Inc
Healthcare · Medical Devices
Manufactures orthopedic implants, surgical instruments, and robotic navigation systems for spine and trauma disorders.
Assets:
Audubon headquartersOperates primary corporate and engineering facilities in Pennsylvania
Excelsius ecosystemIntegrates ExcelsiusGPS robotic navigation and Excelsius3D imaging platforms
NuVasive integrationExpanded international spine footprint and XLIF lateral surgical access systems
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

88
OPS ScoreOperating finances
Latest quote
-2.74%$68.60
$9.09B
16.9×
$3.14B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was GMED. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Globus Medical (GMED) do?

Globus Medical Inc (GMED) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures orthopedic implants, surgical instruments, and robotic navigation systems for spine and trauma disorders. Integrates robotic navigation systems directly with proprietary spinal implants and imaging equipment for orthopedic. It is worth $9.09B on the market and sold $3.14B over the last year.

Market cap
$9.09B
P/E ratio
16.9×
Annual sales
$3.14B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 15, 2026

Brands and businesses behind GMED

  • ExcelsiusGPS: Sells robotic navigation platforms and procedural accessories for spine and cranial operations to hospitals.
  • NuVasive: Generates revenue by selling minimally invasive lateral surgical access systems, hardware implants, and monitoring equipment.
  • Synaptive Medical: Sells specialized cranial imaging, surgical planning software, and robotic microscopes for complex brain procedures.

GMED’s flags, in plain English

Each flag is a number from Globus Medical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Stupid Cash

Can pay this year's bills 4.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 2% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Still Climbing

Sales up 30.1% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Worth a Look

Hospital budget constraints and procurement delays lengthen sales cycles for expensive robotic navigation hardware. Something here could change the picture, so it is worth reading next to the good news.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about GMED

How big is Globus Medical?

Globus Medical’s market cap is $9.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.14B: what customers paid the company over the last year, before any costs.

What is GMED’s P/E ratio?

GMED’s P/E ratio is 16.9×. Investors pay about 16.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with GMED?

The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Globus Medical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GMED’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card